Fundraising Fox
Sensus Healthcare
NASDAQ: SRTSBoca Raton, US · Delaware corporation
Find your way into Sensus Healthcare
256 people in our graph share verified history with the Sensus Healthcare team — schools, employers, funds. One of them is your warm intro.
Nir Yaronunlockedknows Arthur Levine · together at Scitex Corporation (overlapped)
×2knows the team · via Scitex Corporation
knows the team · via Xoft, a subsidiary of iCAD, Inc.
×7knows the team · via Siemens Healthineers
knows the team · via DentaQuest
Sensus Healthcare develops Superficial Radiotherapy (SRT) medical devices, including the SRT-100, SRT-100+ and SRT-100 Vision (which adds high-frequency ultrasound imaging), used to treat non-melanoma skin cancer and keloids without surgery. The devices are sold to physicians, institutions and healthcare systems for non-invasive, in-office outpatient treatment.
Founders & leadership
JC
Joseph C. SardanoCo-founder · Chairman & CEOJoseph Sardano is Chief Executive Officer of Sensus Healthcare, a medical device company developing superficial radiotherapy systems for non-melanoma skin cancer and keloid treatment. He has held senior commercialization and operations roles at Xoft (subsidiary of iCAD) and Siemens Healthineers in oncology, and completed management training at McGill University.
KF
Kalman FishmanChief Technology Officer and Chief Operating Officer
AL
Arthur LevineChief Financial Officer2014–2020Arthur Levine brings Big Four and multinational finance experience, including 10+ years internationally, gained through roles at publicly traded and private companies. He has led finance teams and managed capital raising, M&A, IPO processes, and SEC reporting for companies across medical devices, biopharma, fintech, and other sectors.
Board
JH
John HeinrichBoard director
SO
Samuel O'RearBoard director
WM
William McCallBoard director
Reported raises · per SEC filings
Form D private placements$2.2M disclosed across 1 round · 2015
▶$2.2MraisedJan 2016 · 58 investors · Other TechnologyRule 506(b)
▶$2.2MraisedJan 2016 · 58 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- John HeinrichDirector
- Samuel O'RearDirector
- Arthur LevineExecutive Officer
- Joseph C. SardanoExecutive Officer, Director
- William McCallDirector
- Kalman FishmanExecutive Officer
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- Minimum investment
- $25K
- Sales commissions
- $154K
- Placement agents
- Neidiger, Tucker, Bruner, Inc.
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$71.4Mvaluation at IPOJun 2016 · $5.50/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 4
by search overlapAmerican Cancer Society (ACS)324 shared keywordsThe American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
Medscape262 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Cancerresearchuk257 shared keywordsCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
MD Anderson Cancer Center243 shared keywordsUT MD Anderson is a cancer research and treatment center that provides patient care, conducts research, and offers education in cancer prevention and treatment. It is part of the University of Texas System and operates as a nonprofit medical institution.
Companies competing with Sensus Healthcare for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
We Think Sensus Healthcare (NASDAQ:SRTS) Can Afford To Drive Business Growth - Simply Wall St Newssimplywall.st · Aug 2026
Sensus Healthcare posts larger loss on revenue drop | SRTS Quarterly Report (10-Q)stocktitan.net · Aug 2026Frequently asked questions
- What does Sensus Healthcare do?
- Sensus Healthcare develops Superficial Radiotherapy (SRT) medical devices, including the SRT-100, SRT-100+ and SRT-100 Vision (which adds high-frequency ultrasound imaging), used to treat non-melanoma skin cancer and keloids without surgery. The devices are sold to physicians, institutions and healthcare systems for non-invasive, in-office outpatient treatment.
- Who founded Sensus Healthcare?
- Sensus Healthcare was founded by Joseph C. Sardano, Kalman Fishman.
- How much funding has Sensus Healthcare raised?
- Sensus Healthcare has disclosed $2.2M raised across 1 round.
- Where is Sensus Healthcare headquartered?
- Sensus Healthcare is headquartered in Boca Raton, US.